Hepatitis, caused by the hepatitis A, B, and C viruses, can result in liver-related illnesses like hepatitis A, hepatitis B, hepatitis C, liver cirrhosis, hepatocellular carcinoma, and liver failure, often leading to the death of the infected person. Transmission of the hepatitis A and B viruses occurs through contact with the body fluids of an infected individual. Vaccines are available to prevent both hepatitis A and B, boosting immunity to avoid complications such as liver failure and cancer. The infection is most common in children, and globally, hepatitis B is more widespread than hepatitis A.
Hepatitis is a highly prevalent infectious disease that affects millions of people worldwide, leading to an increasing incidence of the disease and prompting attention from health organizations such as the WHO. The Hepatitis Vaccine Market is expected to grow due to the severity of the disease and the increasing global population, with new vaccines for hepatitis A and B being introduced, leading to more competition and expansion in the market. The cost of the vaccines remains a concern, and government support is necessary to ensure their affordability for all. Availability remains low in remote regions of emerging markets, limiting market growth, but there is potential for an effective hepatitis C vaccine. The current hepatitis B vaccine is ineffective in many adults, indicating the need for a new and improved vaccine to drive market growth. WHO recommends administering the hepatitis B vaccine within 24 hours of birth to prevent infection in infants.
Top Companies in the Hepatitis Vaccine Industry:
Merck and Company
Merck & Co. was established in 1891 and is headquartered in Rahway, New Jersey, United States. It operates in over 191 countries and is engaged in developing medicines, vaccines, biologic therapies, and animal health products.